TG Therapeutics, Inc.
NASDAQTG Therapeutics arrives at its June 11 earnings call having surged 18% on the week to $43.37 — yet the short position that bears rebuilt through late May is essentially unchanged, leaving a loaded confrontation between momentum buyers and a stubborn bear camp heading into tomorrow's print. The positioning picture is one of an entrenched standoff. Short interest barely moved despite…
Snapshot as of 21 Jun 2026
TG Therapeutics arrives at its June 11 earnings call having surged 18% on the week to $43.37 — yet the short position that bears rebuilt through late May is essentially unchanged, leaving a loaded confrontation between…
TG Therapeutics heads into its June 11 earnings call in a starkly different place than it was a week ago — the stock has ripped 18% higher to $43.37 while a large short position remains firmly in place, setting up a…
TG Therapeutics enters its June 11 earnings call with a notable reversal underway — the short-covering trend that defined May has stalled, bears are rebuilding positions, and the stock has given back nearly 8% on the…
TG Therapeutics heads into its June 11 earnings call in a notably different posture than it entered May — short sellers are quietly covering, options traders have swung decisively bullish, and the stock is up more than…
TG Therapeutics reported Q1 2026 results today with a notable split: revenue of $204.9 million beat the $196.8 million consensus estimate, while adjusted EPS of $0.18 missed the $0.30 estimate by a wide margin. The…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for TGTX — free to start on ORTEX.
Sign up for free →Open TGTX on ORTEX